Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ – Get Rating) CEO Timothy Warbington bought 25,000 shares of the business’s stock in a transaction on Monday, June 6th. The stock was bought at an average cost of $0.92 per share, with a total value of $23,000.00. Following the completion of the purchase, the chief executive officer now directly owns 25,087 shares in the company, valued at $23,080.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of OTCMKTS:CELZ traded down $0.04 during midday trading on Tuesday, reaching $0.88. 191,832 shares of the company’s stock were exchanged, compared to its average volume of 3,662,505. The firm’s 50 day simple moving average is $2.04 and its two-hundred day simple moving average is $2.20. Creative Medical Technology Holdings, Inc. has a fifty-two week low of $0.88 and a fifty-two week high of $21.00.
A number of analysts recently issued reports on the company. Zacks Investment Research raised Creative Medical Technology from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research report on Friday. Roth Capital assumed coverage on Creative Medical Technology in a research report on Friday, February 25th. They set a “buy” rating and a $10.00 price objective for the company.
Creative Medical Technology Company Profile (Get Rating)
Creative Medical Technology Holdings, Inc, a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility.
- Get a free copy of the StockNews.com research report on Creative Medical Technology (CELZ)
- It’s Time To PLAY With Dave & Buster’s
- Seagate Technology: Improved Fundamentals & Recovering Technicals
- It’s A Sweet Time To Buy The J.M. Smucker Co.
- Don’t Rush Out To Buy G-III Apparel
- Target’s Warning Is Dire News For The S&P 500
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.